Intercontinental Wealth Advisors LLC decreased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 9.3% in the third quarter, Holdings Channel.com reports. The firm owned 2,631 shares of the medical research company’s stock after selling 271 shares during the period. Intercontinental Wealth Advisors LLC’s holdings in Icon were worth $388,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. SRS Capital Advisors Inc. bought a new position in shares of Icon during the second quarter valued at approximately $47,000. UBS Asset Management Americas Inc. increased its stake in shares of Icon by 30.9% during the second quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 77 shares in the last quarter. Coastal Capital Group Inc. bought a new position in shares of Icon during the second quarter valued at approximately $78,000. Steward Partners Investment Advisory LLC bought a new position in shares of Icon during the second quarter valued at approximately $172,000. Finally, DekaBank Deutsche Girozentrale increased its position in shares of Icon by 72.7% during the second quarter. DekaBank Deutsche Girozentrale now owns 1,328 shares of the medical research company’s stock valued at $201,000 after acquiring an additional 559 shares in the last quarter. 83.37% of the stock is owned by institutional investors and hedge funds.
Shares of ICLR traded up $2.07 on Wednesday, hitting $146.83. 109,215 shares of the stock traded hands, compared to its average volume of 264,911. The company has a market capitalization of $7.81 billion, a PE ratio of 23.34, a P/E/G ratio of 2.03 and a beta of 0.67. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.07 and a current ratio of 2.07. The business has a 50 day simple moving average of $151.86 and a 200 day simple moving average of $146.41. Icon Plc has a one year low of $118.10 and a one year high of $165.13.
ICLR has been the subject of several analyst reports. ValuEngine downgraded shares of Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, September 11th. Mizuho raised their price target on shares of Icon from $160.00 to $170.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Zacks Investment Research downgraded shares of Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, September 18th. UBS Group raised shares of Icon from a “sell” rating to a “neutral” rating and raised their price target for the company from $135.00 to $171.00 in a research report on Friday, July 26th. Finally, BidaskClub downgraded shares of Icon from a “buy” rating to a “hold” rating in a research report on Monday, September 30th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $165.29.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More: Google Finance Portfolio Workaround
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.